Ah, the stock market. A bastion of rational thought, economic fundamentals, and predictable patterns. Or so they say. Then there’s the market under the influence of Donald J. Trump, where traditional wisdom often takes a vacation, and the only constant is the delightful unpredictability of policy pronouncements, often delivered with the subtlety of a bullhorn on social media. As 2025 draws to a close, we’ve once again witnessed the unique spectacle of markets gyrating to the rhythm of presidential decrees, tariff threats, and the occasional pharmaceutical handshake.
The Pharma Paradox: Deals, Discounts, and Dubious Savings
In a move that surprised absolutely no one familiar with the current administration’s playbook, President Trump recently announced a fresh batch of drug price deals. On December 19, 2025, nine more pharmaceutical giants, including AMGN, BMY, GILD, GSK, MRK, NVS, and SNY, joined the growing list of companies agreeing to “lower” drug prices for Medicaid and cash payers. This follows earlier agreements with five others, notably PFE, and involves aligning U.S. drug costs with those in other developed nations. The carrot, of course, is a sweet three-year exemption from potential import tariffs, a threat often brandished to bring these corporate titans to the negotiating table.
The market’s reaction to these “landmark” deals has been, predictably, a mixed bag of shrugs and minor tremors. Back on September 30, 2025, PFE shares, for instance, saw a respectable surge of approximately 5.3%, closing near $25.05 per share, after its initial deal and a hefty $70 billion commitment to U.S. manufacturing were announced. One might assume that such a substantial investment would be the primary driver, rather than the promise of lower prices for a segment of the market already enjoying significant discounts.
However, not all pharma players received the same warm embrace. NVO, the Danish powerhouse behind popular GLP-1 weight-loss drugs like Wegovy and Zepbound, experienced a rather deflating moment. Its shares fell as much as 3% on November 7, 2025, after agreeing to slash prices for government programs and cash payers. Analysts, ever the optimists, noted that while this might be a “near-term headwind,” it could “potentially boost volumes in the longer term”. Because nothing says innovation like forced discounts and the hope of selling more units at a lower margin.
The irony, as always, is not lost on those paying attention. Analysts have been quick to point out that Medicaid, the program touted as a beneficiary, already enjoys substantial price discounts, sometimes exceeding 80%. Furthermore, the overall savings to the U.S. health system from these voluntary agreements are widely considered “negligible”. As one expert sagely remarked, “I don’t see much downside but it’s hard to judge what the upside is”. In essence, a lot of fanfare for what might amount to a rounding error in the grand scheme of healthcare spending, but excellent optics for a president keen on demonstrating action.
The Tariff Tango: Two Steps Forward, Three Steps Back, and a $5 Trillion Wipeout
If there’s one thing the markets have learned about a Trump administration, it’s to brace for tariffs. And 2025 did not disappoint. On April 2, President Trump unveiled a new trade policy so sweeping, it included a universal 10% tariff on all U.S. imports, alongside “reciprocal tariffs” that would make even the most seasoned trade negotiator blush – 104% on China, 20% on the European Union, and 24% on Japan. This pushed the effective overall U.S. tariff rate to an estimated 25%, the highest in over a century. The market, naturally, reacted with a collective gasp, sending the S&P 500 plummeting by more than 10% over two days, wiping out a cool $5 trillion from the markets in one of its worst performances since World War II.
But fear not, for the drama was far from over. Just a week later, on April 9, a sudden announcement of a 90-day pause on most new reciprocal tariffs (excluding China, because some relationships are just too complicated) triggered an immediate and “violent” market surge. The S&P 500 rocketed up 9.52%, adding approximately $4.3 trillion in value, the Nasdaq exploded 12.16% higher, and the Dow Jones Industrial Average jumped nearly 3,000 points. It was a rally so enthusiastic, it almost made you forget the preceding $5 trillion haircut.
However, the market’s memory is short, but China’s is apparently even shorter. The very next day, April 10, U.S. stocks surrendered a significant portion of these historic gains after China announced countermeasures and the White House clarified that tariffs on Chinese imports would be 145%, not the initially “announced” 125%. The S&P 500 fell 3.5%, the Dow Jones dropped 2.5%, and the Nasdaq sank 4.3%. It seems the market prefers its tariff threats to be consistently inconsistent, rather than consistently high.
The impact of these trade policies has been a masterclass in economic whiplash. Tariffs have consistently led to increased consumer prices and heightened market volatility. As Ken Griffin, the head of Citadel, so eloquently put it, “The administration’s attempts to use tariffs come at a dear price to the US economy and consumer”. Goldman Sachs, ever the purveyor of cold, hard numbers, estimated that every 5 percentage point increase in the U.S. tariff rate could reduce S&P 500 earnings per share by 1-2%. Meanwhile, the U.S. manufacturing sector, which these tariffs were supposedly designed to protect, has reportedly seen up to 15% cost increases due to imported components and has shed 67,000 jobs since April 1, 2025. Manufacturers, in a move that will surely delight consumers, are now planning price hikes to offset these rising costs. The CBOE Volatility Index (VIX), Wall Street’s “fear gauge,” surged dramatically in April 2025, reaching levels not seen since the early 2020 pandemic crash. Because nothing calms investor nerves like a good old-fashioned trade war.
Truth Social: Where Valuation Meets… Something Else
No discussion of Trump’s market impact would be complete without a nod to his digital soapbox, Truth Social, and its publicly traded parent company. Digital World Acquisition Corp. (DWAC) officially merged with Trump Media & Technology Group (TMTG) in March 2024, and now trades under the ticker DJT. Its journey on the public markets has been, shall we say, unique.
On December 19, 2025, DJT announced a rather unexpected $6 billion all-stock merger with TAE Technologies, a fusion energy company. The market, clearly enthralled by the prospect of a social media platform venturing into nuclear physics, sent the stock soaring 42%, closing at $14.86. This, of course, is just another chapter in the DJT saga, a stock that analysts have noted often operates “with no connection to any financial or valuation metrics”.
Earlier in the year, on April 9, 2025, amidst the tariff-induced market chaos, Trump took to Truth Social to declare, “THIS IS A GREAT TIME TO BUY!!! DJT.” His company’s shares, in a truly remarkable display of market sentiment, outperformed the broader market, soaring 22.67% that very day. The parent company of Truth Social boasted a market value of over $4.5 billion as of December 20, 2025 [cite: alert_2]. With predictions for DWAC‘s (now DJT) price in 2025 ranging from a conservative $29.78 to an optimistic $100.33, it’s clear that traditional valuation models are merely suggestions in this particular corner of the market. As of December 18, 2025, the sentiment was bullish, with 22 technical indicators signaling positive movement. It seems that for DJT, the market isn’t just pricing in future earnings, but perhaps also the sheer entertainment value of its chairman’s pronouncements.
Conclusion: The Art of the Deal, Redefined
In the unpredictable theater of the stock market, Donald Trump continues to play a starring role, often as both the protagonist and the antagonist. His impact is undeniable, characterized by sudden policy shifts, bold declarations, and market reactions that defy conventional logic. From “negotiating” drug prices that offer debatable savings to instigating tariff wars that wipe out trillions only to be partially reversed, the market under Trump is less about steady growth and more about a rollercoaster ride with unexpected loops and drops. Investors, it seems, have learned to strap in, hold tight, and perhaps keep an eye on Truth Social for the next market-moving pronouncement. Because in this market, the only thing more volatile than the headlines is the sentiment that follows them.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.